Skip to main content
. 2020 Feb 21;64(3):e02072-19. doi: 10.1128/AAC.02072-19

FIG 3.

FIG 3

Kill curve activity of simulations for CFZ administered at 2 g every 8 h and OXA administered at 2 g every 6 h in an ex vivo SEV model in host-mimicking RPMI–10% LB media against MRSA strains 11-11 (A), MW2 (B), COL (C), and BMC-1001 (D). *, P < 0.05 versus control.